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Summary	  	  Current	  cancer	  therapies	  target	  the	  bulk	  of	  the	  tumour,	  while	  a	  population	  of	  highly	  resistant	  tumour	  cells	  maybe	  able	  to	  repopulate	  the	  tumour	  and	  metastasise	  to	  new	  sites.	  Cancer	  cells	  with	  such	  stem	  cell-­‐like	  characteristics	  can	  be	  identified	  based	  on	  their	  phenotypic	  and/or	  functional	  features	  which	  may	  open	  up	  ways	  for	  their	  targeted	  elimination.	  In	  this	  review	  we	  discuss	  potential	  off-­‐target	  effects	  of	  inhibiting	  cancer	  stem-­‐cell	  self-­‐renewal	  pathways	  on	  immune	  cells,	  and	  summarise	  some	  recent	  immunological	  studies	  specifically	  targeting	  cancer	  stem	  cells	  based	  on	  their	  unique	  antigen	  expression.	  	  
	  
1.	  Introduction	  	  Cancer	  stem	  cells	  (CSCs),	  also	  called	  stem-­‐like	  cells	  or	  tumour-­‐initiating	  cells	  (TICs),	  are	  a	  distinct	  subpopulation	  of	  tumour	  cells.	  They	  may	  arise	  in	  a	  variable	  and	  unpredictable	  manner	  due	  to	  genetic	  and	  epigenetic	  changes	  during	  tumour	  development	  (stochastic	  theory),	  or	  they	  are	  cells	  that	  possess	  a	  unique	  intrinsic	  ability	  to	  initiate	  tumour	  growth	  and	  self-­‐renewal	  (hierarchical	  theory).	  The	  existence	  of	  CSCs	  has	  been	  postulated	  for	  a	  while	  before	  experimental	  evidence	  was	  first	  provided	  in	  1994.	  A	  subpopulation	  of	  acute	  myeloid	  leukemia	  cells,	  with	  CD34high	  CD32low	  phenotype,	  was	  shown	  to	  be	  highly	  capable	  of	  engrafting	  leukemia	  in	  SCID	  mice	  (1).	  These	  cells	  were	  called	  leukemia-­‐initiating	  cells.	  Solid	  tumour	  TICs	  were	  first	  described	  in	  breast	  cancer	  (CD44+CD24-­‐/low/Linage-­‐	  cells)	  in	  2003	  (2),	  followed	  by	  further	  discoveries	  in	  a	  variety	  of	  malignancies.	  As	  for	  using	  the	  correct	  designation,	  CSCs	  are	  perceived	  as	  immature	  progenitors	  of	  tumour	  cells,	  residing	  at	  the	  top	  of	  a	  hierarchical	  organisation	  of	  tumour	  cell	  differentiation.	  On	  the	  other	  hand,	  the	  definition	  of	  TICs	  is	  based	  on	  the	  function	  of	  these	  cells,	  as	  they	  are	  uniquely	  capable,	  at	  very	  low	  cell	  numbers,	  to	  initiate	  heterogenous,	  complex	  tumours	  in	  vivo.	  In	  this	  review,	  we	  use	  the	  combined	  CSCs/TICs	  abbreviation,	  as	  suggested	  by	  Maccalli	  et	  al.	  (3)	  reflecting	  the	  variety	  of	  the	  references.	  	   While	  traditional	  cancer	  therapies,	  such	  as	  radio-­‐	  or	  chemotherapy,	  may	  eliminate	  the	  bulk	  of	  the	  tumours,	  treatment	  resistance	  in	  CSCs/TICs	  is	  thought	  to	  be	  responsible	  for	  relapse.	  In	  order	  to	  prevent	  or	  significantly	  delay	  relapse,	  these	  cells	  should	  be	  specifically	  targeted	  and	  eliminated.	  There	  are	  numerous	  ongoing	  trials,	  targeting	  CSCs/TICs	  (for	  latest	  review	  see	  (4)),	  however,	  in	  order	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to	  design	  efficient	  novel	  treatment	  approaches,	  we	  need	  a	  better	  understanding	  of	  the	  biology	  of	  these	  cells.	  In	  this	  review	  we	  summarise	  the	  current	  state	  of	  knowledge	  about	  the	  feasibility	  of	  immune	  targeting	  CSCs/TICs	  in	  solid	  tumours.	  We	  also	  point	  out	  how	  some	  of	  the	  biological	  targeting	  of	  CSCs/TICs	  may	  act	  as	  a	  double	  edge	  sword	  by	  also	  affecting	  immune	  responses.	  	  	  
2.	  Developmental	  pathways	  in	  CSC/TIC	  signalling	  
	  Developmental	  pathways	  play	  important	  roles	  in	  normal	  stem	  cell	  function.	  The	  core	  stem	  cell	  pathways,	  Notch,	  Wnt/β-­‐catenin,	  Hedgehog	  (discussed	  in	  more	  detail	  below)	  and	  some	  other	  crucial	  pathways,	  such	  as	  JAK/STAT,	  PI3K/PTEN	  and	  NFκB,	  promote	  cell	  proliferation	  and	  the	  formation	  of	  CSC-­‐like	  colonies	  (5,	  6).	  They	  are	  frequently	  altered	  in	  cancers,	  such	  as	  become	  deregulated	  or	  persistently	  activated	  and	  suggested	  to	  be	  responsible	  for	  CSC/TIC	  regulation	  (7-­‐10).	  
	  
Notch	  –	  Notch	  ligands,	  located	  in	  the	  plasma	  membrane	  of	  adjacent	  cells	  are	  trans-­‐activated,	  triggering	  the	  transcription	  of	  Notch	  target	  genes,	  such	  as	  the	  HES	  (hairy	  and	  enhancer	  of	  split)-­‐related	  family,	  c-­‐myc,	  PI3K,	  AKT,	  NF-­‐κB,	  PPAR,	  CyclinD1,	  p21	  and	  p27.	  The	  activation	  of	  these	  downstream	  targets	  regulates	  cell	  fate	  leading	  to	  differentiation,	  cell-­‐cycle	  progression	  and	  survival,	  depending	  on	  the	  particular	  signalling	  context.	  In	  stem-­‐like	  cells	  Notch	  may	  delay	  differentiation	  and	  promote	  cell	  survival	  (11,	  12).	  There	  are	  numerous	  ongoing	  phase	  I	  and	  II	  clinical	  trials	  in	  cancer	  with	  a	  range	  of	  targets	  and	  mechanisms	  investigating	  the	  usefulness	  of	  Notch	  targeting,	  alone	  or	  in	  combination	  with	  other	  therapies	  (11).	  However,	  Notch	  signalling	  has	  also	  been	  linked	  to	  peripheral	  T	  cell	  maturation	  into	  effector	  cells,	  such	  as	  developing	  cytotoxic	  T	  cell	  function	  or	  cytokine	  production	  (13).	  T	  cell	  activity	  has	  been	  shown	  to	  be	  impaired	  by	  Notch-­‐inhibition	  with	  a	  γ-­‐secretase	  inhibitor	  (14).	  	  
	  
Wnt	  –	  two	  pathways	  have	  been	  identified:	  the	  canonical	  one	  is	  β-­‐catenin	  dependent	  and	  involved	  in	  cell	  fate	  determination.	  The	  non-­‐canonical	  pathway	  is	  
β-­‐catenin	  independent	  and	  involved	  in	  cell	  movement	  and	  polarity.	  Wnt	  signalling	  is	  initiated	  by	  soluble	  ligands	  released	  by	  neighbouring	  cells.	  In	  cancer,	  gain	  of	  function	  and	  loss	  of	  function	  mutations,	  regulation	  by	  methylation	  and	  histone	  modification	  of	  this	  pathway	  have	  all	  been	  observed	  (9,	  15,	  16).	  Its	  inhibition	  in	  CSCs	  is	  a	  main	  area	  of	  cancer	  therapy	  research	  (17).	  However,	  the	  Wnt/β-­‐catenin	  pathway	  is	  also	  a	  key	  regulator	  of	  T	  cell	  development	  and	  activation.	  Wnt/β-­‐catenin	  signalling	  is	  crucial	  for	  CD8+	  memory	  T	  cell	  development	  (18),	  while	  agonists	  of	  the	  pathway	  improve	  immunotherapy	  outcomes	  (19).	  	  	  The	  Hedgehog	  (Hh)	  signalling	  pathway	  has	  been	  implicated	  in	  tissue	  homeostasis	  and	  repair	  and	  epithelial	  to	  mesenchymal	  transition	  (EMT)	  in	  normal	  tissues.	  In	  cancer,	  aberrant	  signalling	  such	  as	  overexpression	  of	  its	  ligands,	  loss	  of	  function	  of	  the	  receptor	  and	  dysregulation	  of	  transcription	  factors	  	  promote	  tumorigenesis	  and	  tumour	  progression.	  Hh	  signalling	  can	  also	  be	  canonical	  and	  non-­‐canonical,	  and	  triggered	  by	  a	  variety	  of	  factors	  in	  the	  tumour	  microenvironment,	  such	  as	  TGF-­‐β,	  TNF-­‐α,	  and	  IL-­‐6.	  Inhibition	  of	  Hh	  signalling	  is	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also	  undergoing	  intense	  investigations	  for	  cancer	  treatment	  (20).	  Hh	  signalling	  is	  relevant	  in	  immune	  cell	  development	  and	  function,	  although	  its	  effect	  on	  peripheral	  T	  cell	  function	  is	  controversial	  (21-­‐24).	  As	  it	  is	  also	  involved	  in	  myeloid	  derived	  suppressor	  cell	  (MDSC)	  function	  (25),	  Hh	  inhibitors	  may	  deliver	  additional	  benefits.	  	  	  As	  there	  is	  a	  considerable	  overlap	  between	  these	  pathways,	  single	  targeting	  is	  unlikely	  to	  achieve	  a	  physiologically	  relevant	  level	  of	  inhibition.	  Furthermore,	  the	  fact	  that	  they	  are	  also	  involved	  in	  normal	  tissue	  homeostasis	  and	  development,	  including	  immune	  cell	  behaviour	  and	  peripheral	  effector	  function,	  makes	  their	  targeting	  a	  difficult	  challenge.	  	  
	  
3.	  Identification	  and	  isolation	  of	  CSCs/TICs	  
	  
(a)	  Surface	  marker-­‐based	  identification	  
	  CSCs/TICs	  are	  typically	  isolated	  based	  on	  their	  expression	  of	  proteins	  shared	  in	  common	  with	  healthy	  stem	  cells.	  The	  markers	  most	  commonly	  used	  across	  solid	  tumours	  to	  identify	  CSCs/TICs	  are	  CD133,	  CD44,	  IL-­‐6R,	  CD24,	  EpCAM,	  Lgr5,	  CD166	  and	  CD29,	  alone	  or	  in	  combinations.	  The	  use	  of	  these	  markers	  is	  relatively	  conserved	  across	  the	  spectrum	  of	  solid	  cancers.	  However,	  there	  are	  technical	  considerations	  which	  may	  give	  rise	  to	  false	  positives	  or	  inconsistencies	  in	  the	  results	  including	  subjectivity	  in	  flow	  cytometry	  gating,	  the	  use	  of	  cell	  lines	  vs.	  primary	  cells,	  confirmation	  of	  function	  in	  clonogenic	  cultures	  and	  animal	  models.	  For	  some	  of	  these	  markers	  there	  is	  evidence	  for	  direct	  stem	  cell-­‐like	  function,	  while	  recently	  the	  validity	  of	  some,	  as	  bona	  fide	  CSC/TIC	  markers,	  has	  been	  called	  into	  question,	  as	  discussed	  later.	  A	  few	  common	  markers	  are	  discussed	  below.	  	  
CD133	  CD133	  (Prominin-­‐1)	  is	  a	  five-­‐transmembrane	  glycoprotein	  used	  to	  identify	  CSCs/TICs	  in	  prostate,	  pancreatic,	  colon	  and	  liver	  cancers	  and	  glioblastoma	  (5).	  Although	  the	  precise	  function	  of	  CD133	  has	  not	  been	  elucidated,	  it	  is	  known	  to	  bind	  cholesterol	  and	  is	  localised	  in	  protrusions	  of	  the	  membrane	  e.g.	  in	  villi	  and	  cilia.	  Despite	  its	  initial	  acceptance	  as	  a	  CSC/TIC	  marker,	  in	  some	  instances	  cells	  expressing	  this	  marker	  have	  not	  demonstrated	  exclusive	  tumour	  initiating	  ability	  (26,	  27).	  CD133	  is	  also	  present	  in	  a	  number	  of	  adult	  tissues	  including	  the	  kidneys,	  pancreas	  and	  colon	  (28,	  29)	  and	  it	  is	  used	  as	  a	  marker	  for	  haematopoietic	  stem	  cells.	  Thus	  it	  is	  important	  to	  acknowledge	  that	  it	  is	  not	  a	  universal	  CSC	  marker	  nor	  is	  it	  a	  cancer	  cell	  specific	  antigen.	  	  	  Some	  of	  the	  inconsistencies	  observed	  in	  the	  application	  of	  CD133	  as	  a	  CSC/TIC	  marker	  may	  be	  associated	  with	  its	  pattern	  of	  expression	  and	  the	  antibodies	  used	  to	  detect	  it	  (30).	  The	  most	  commonly	  used	  antibodies	  for	  CD133	  detection	  are	  mouse	  monoclonal	  antibodies	  ‘CD133/1’	  and	  ‘CD133/2’,	  which	  detect	  the	  epitopes	  AC133	  and	  AC141	  respectively.	  These	  epitopes	  are	  distinct	  of	  each	  other	  and	  both	  are	  glycosylated.	  Different	  glycosylation	  status	  of	  CD133	  across	  different	  tissues	  may	  give	  rise	  to	  false	  negatives.	  Glycosylation	  status	  is	  also	  suggested	  to	  change	  as	  a	  result	  of	  differentiation	  in	  some	  lineages	  (31,	  32),	  
	   4	  
although	  this	  may	  be	  advantageous	  in	  the	  specific	  detection	  of	  early	  progenitor	  cells.	  However,	  a	  number	  of	  studies	  have	  shown	  that	  AC133	  epitope	  expression	  (as	  detected	  by	  the	  CD133/1	  antibody)	  doesn’t	  correlate	  with	  CD133	  protein	  or	  mRNA	  levels	  (32).	  The	  functional	  outcome	  of	  the	  loss	  of	  this	  epitope	  upon	  differentiation	  is	  unclear.	  
	  
CD44	  CD44	  is	  used	  to	  identify	  CSCs/TICs	  in	  breast,	  prostate,	  colon,	  head	  and	  neck	  and	  pancreatic	  cancer.	  CD44	  is	  a	  transmembrane	  glycoprotein	  that	  functions	  as	  a	  receptor	  for	  hyaluronic	  acid.	  It	  has	  a	  multitude	  of	  physiological	  and	  pathological	  functions	  including	  adhesion	  and	  migration,	  proliferation,	  growth	  and	  survival.	  However,	  CD44	  is	  widely	  expressed	  in	  healthy	  tissues	  and	  in	  multiple	  cell	  types	  in	  the	  cancer	  microenvironment,	  making	  it	  difficult	  to	  apply	  as	  a	  specific	  CSC/TIC	  marker.	  CD44	  is	  subject	  to	  alternate	  splicing	  and	  it	  has	  been	  suggested	  that	  CD44	  splice	  variants	  ‘CD44v’	  specifically	  identify	  cells	  with	  greater	  tumorigenic	  potential	  compared	  to	  cells	  expressing	  ‘CD44s’,	  the	  standard	  isoform	  (33,	  34).	  Additionally,	  certain	  splice	  variants	  have	  been	  suggested	  to	  have	  pathological	  functions	  in	  colon	  and	  pancreatic	  cancer	  (35)	  and	  have	  prognostic	  utility	  in	  other	  cancers	  including	  NSCLC,	  AML	  and	  gastric	  cancer	  (34).	  CD44high	  cells	  were	  shown	  to	  be	  less	  immunogenic	  than	  CD44low	  tumour	  cells	  in	  head	  and	  neck	  cancer,	  partially	  via	  enhanced	  expression	  of	  the	  programme	  cell	  death	  ligand	  -­‐1	  (PD-­‐L1)	  (36).	  A	  Phase	  I	  trial	  of	  a	  humanised	  IgG1	  antibody,	  targeting	  the	  extracellular	  hyaluronic	  acid	  binding	  domain	  of	  all	  CD44	  isoforms	  (37)	  in	  heavily	  pretreated	  cancer	  patients,	  proved	  to	  be	  safe	  but	  had	  only	  modest	  clinical	  effects.	  On	  the	  other	  hand	  however,	  CD44	  also	  regulates	  Th1	  cell	  survival,	  memory	  function	  (38),	  T	  cell	  IL-­‐17	  and	  IFNγ	  production	  thus	  its	  targeting	  may	  impair	  anti-­‐tumour	  immune	  responses	  (39).	  
 
IL-­‐6R	  IL-­‐6	  has	  been	  shown	  to	  enhance	  stemness	  markers	  (Notch,	  Lgr5	  and	  Oct-­‐4)	  in	  colon	  cancer	  (40)	  and	  the	  survival	  and	  tumorigenicity	  of	  cancer	  stem	  cells	  identified	  as	  ALDHhigh/CD44high	  in	  head	  and	  neck	  carcinoma	  (41).	  Inhibition	  of	  IL-­‐6	  signalling	  with	  an	  IL-­‐6R	  inhibitor	  antibody	  (tocilizumab)	  prevents	  human	  CSC-­‐mediated	  tumour	  initiation	  (41).	  Similar	  observations	  were	  made	  in	  an	  NSCLC	  cell	  line,	  where	  inhibition	  of	  IL-­‐6	  or	  IL-­‐6R,	  separately	  or	  in	  combination,	  significantly	  inhibited	  CSC	  proliferation	  and	  growth	  (42).	  In	  colon	  cancer,	  blocking	  IL-­‐6	  receptor	  with	  a	  monoclonal	  antibody	  reduced	  spheroid	  formation,	  stem	  cell-­‐related	  gene	  expression	  and	  enhanced	  resistance	  to	  chemotherapy	  by	  5-­‐fluorouracil	  (40).	  However,	  IL-­‐6R	  also	  plays	  an	  important	  role	  in	  naïve	  and	  central	  memory	  T	  cells,	  regulating	  their	  survival,	  proliferation	  and	  effector	  function	  while	  also	  blocking	  Treg	  function	  (43).	  	  
Further	  markers	  	  There	  is	  a	  huge	  array	  of	  further	  markers	  that	  have	  been	  used	  alone	  or	  in	  combination	  in	  a	  variety	  of	  cancers	  to	  identify	  CSCs/TICs.	  They	  include	  CD24,	  EpCAM,	  Lgr5,	  CD90,	  CD117,	  CD166,	  CD29,	  CD177,	  ESA,	  AFP,	  Nestin,	  CXCR4,	  and	  SSEA4.	  However,	  the	  plasticity	  of	  these	  markers	  means	  that	  they	  can	  be	  upregulated	  on	  cells	  originally	  not	  expressing	  them	  (44).	  Their	  heterogeneous	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expression	  throughout	  the	  tumour	  tissue	  (45)	  has	  also	  been	  observed,	  making	  their	  isolation	  more	  difficult	  due	  to	  being	  a	  moving	  target.	  From	  the	  point	  of	  view	  of	  our	  review,	  some	  of	  these	  markers,	  when	  unique	  or	  overexpressed,	  can	  serve	  as	  CSC/TIC-­‐associated	  antigens	  for	  T	  cell	  recognition,	  as	  discussed	  later.	  
	  
	  
(b)	  Metabolism-­‐based	  identification	  
	  
Aldehyde	  dehydrogenase	  	  The	  aldehyde	  dehydrogenase	  (ALDH)	  family	  consists	  of	  19	  genes	  (in	  humans)	  that	  express	  enzymes	  which	  catalyse	  the	  oxidation	  of	  aldehyde	  (46).	  Aldehyde	  oxidation	  is	  required	  to	  metabolise	  many	  physiological	  substrates,	  such	  as	  vitamins,	  lipids	  and	  amino	  acids	  (46).	  These	  enzymes	  also	  catabolise	  aldehydes	  derived	  from	  pharmacological	  substrates;	  overall	  they	  have	  a	  protective	  detoxifying	  effect.	  High	  ALDH	  activity	  is	  associated	  with	  both	  normal	  stem	  cells	  and	  CSCs.	  ALDH	  activity	  has	  been	  used	  to	  identify	  CSCs	  in	  breast,	  colon,	  head	  and	  neck,	  pancreatic	  and	  liver	  cancer.	  It	  is	  measured	  using	  the	  flow	  cytometry-­‐based	  ALDEFLUOR	  assay.	  An	  advantage	  this	  assay	  has	  over	  phenotypic	  detection	  methods	  is	  the	  direct	  readout	  of	  a	  fluorescent	  signal,	  based	  on	  enzyme	  activity.	  This	  may	  be	  less	  susceptible	  to	  inconsistencies	  encountered	  by	  antibody-­‐based	  staining,	  such	  as	  epitope	  downregulation	  or	  masking,	  or	  expression	  of	  splice	  variants.	  The	  ALDEFLUOR	  assay	  mainly	  measures	  the	  activity	  of	  the	  ALDH1	  family,	  as	  the	  inhibitor	  DEAB	  used	  in	  the	  assay	  is	  a	  specific	  inhibitor	  of	  ALDH1	  (47).	  However,	  this	  may	  mean	  that	  the	  frequency	  of	  ALDH	  high	  cells	  is	  underestimated	  in	  tissues	  in	  which	  the	  predominant	  ALDH	  isozyme	  is	  not	  of	  the	  ALDH1	  family.	  	  ALDH	  activity	  has	  been	  used	  to	  identify	  CSCs	  in	  a	  number	  of	  cancer	  types.	  In	  prostate	  cancer,	  ALDHhigh	  population	  frequency	  varies	  from	  1.2%-­‐8.3%	  in	  the	  classic	  prostate	  cancer	  cell	  lines	  (DU145,	  PC3,	  LNCaP	  and	  22RV.1)	  while	  cell	  lines	  derived	  from	  metastatic	  prostate	  cancer	  cells	  had	  even	  higher	  ALDHhigh	  frequency;	  up	  to	  30%	  (48,	  49).	  ALDHhigh	  PCa	  CSCs	  have	  demonstrated	  greater	  clonogenicity	  and	  migration	  in	  vitro,	  expression	  of	  stemness-­‐associated	  genes,	  in	  
vivo	  tumour	  initiation	  (49-­‐51)	  and	  induction	  of	  metastasis	  (48).	  ALDH	  activity	  has	  been	  correlated	  with	  the	  expression	  of	  other	  CSC	  or	  clinical	  markers;	  CD44,	  EpCaM	  and	  integrin	  expression	  were	  significantly	  higher	  in	  ALDHhigh	  compared	  to	  ALDHlow	  cells	  in	  one	  report	  (48),	  while	  CD44	  and	  α2-­‐integrin	  levels	  didn’t	  differ	  in	  another	  PCa	  cell	  line	  (50).	  CD133	  was	  not	  detectable	  in	  both	  of	  these	  studies;	  in	  primary	  samples	  it	  was	  detected	  in	  freshly	  isolated	  cells	  but	  was	  greatly	  reduced	  upon	  passaging	  of	  the	  cells	  (52).	  In	  ovarian	  cancer,	  both	  ALDH	  activity	  and	  CD133	  expression	  were	  detected	  in	  primary	  specimens.	  Upon	  passage	  of	  the	  primary	  cells,	  CD133	  expression	  was	  reduced	  but	  it	  could	  be	  rescued	  by	  ‘CSC’	  culture	  conditions	  i.e.	  sphere	  culture	  and	  serum	  free	  conditions	  (53).	  ALDHhigh	  ovarian	  cancer	  cells,	  which	  range	  in	  frequency	  from	  0.1	  to	  7.9%	  in	  cell	  lines	  and	  1-­‐7%	  in	  primary	  samples,	  demonstrated	  tumorigenicity	  in	  vivo	  (53,	  54).	  High	  ALDH	  activity	  has	  been	  used	  to	  identify	  both	  stem	  and	  cancer	  stem	  cells	  in	  breast	  cancer	  with	  frequencies	  of	  8%	  and	  4%	  ALDHhigh	  cells	  respectively(55).	  ALDHhigh	  CD44+	  CD24-­‐	  and	  ALDHhigh	  CD44+	  CD133+	  breast	  cancer	  cells	  demonstrated	  greater	  tumorigenicity	  than	  the	  corresponding	  low/	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negative	  populations	  (56).	  Conflicting	  evidence	  exists	  for	  the	  utility	  of	  ALDH	  activity	  as	  a	  CSC	  marker	  in	  lung	  cancer	  (57).	  In	  one	  study,	  both	  ALDHhigh	  and	  ALDHlow	  cells	  (from	  a	  single	  cell	  line)	  were	  capable	  of	  initiating	  tumours	  in	  vivo	  (58)	  while	  in	  another,	  ALDHhigh	  but	  not	  ALDHlow	  cells	  from	  two	  different	  cell	  lines	  demonstrated	  tumorigenicity	  in	  vivo	  (59).	  One	  further	  study	  using	  8	  lung	  cancer	  cell	  lines	  identified	  STAT3	  signalling	  as	  a	  mediator	  of	  ALDH3A1	  activity	  and	  demonstrated	  tumorigenicity	  in	  two	  cell	  lines	  (60).	  This	  suggests	  that	  variability	  in	  cell	  lines	  could	  lead	  to	  rejection	  of	  a	  potentially	  applicable	  CSC	  marker	  and	  highlights	  the	  importance	  of	  testing	  in	  multiple	  cell	  lines/	  primary	  tissues.	  	  	  ALDH	  expression	  has	  also	  been	  correlated	  with	  clinical	  outcome	  in	  a	  number	  of	  cancers.	  	  High	  ALDH	  expression	  (as	  well	  as	  the	  presence	  of	  other	  CSC	  markers)	  correlates	  with	  poor	  prognosis	  in	  pancreatic	  cancer	  (61)	  and	  both	  in	  serous	  (n=62)	  and	  clear	  cell	  (n=37)	  ovarian	  carcinoma	  cases	  (54)	  and	  in	  112	  serous	  carcinoma	  cases	  in	  a	  further	  study	  (62).	  In	  prostate	  cancer,	  ALDH	  expression	  correlates	  with	  more	  advanced	  stage,	  compared	  to	  localised	  cancer	  and	  BPH	  (63),	  while	  there	  seems	  to	  be	  no	  consensus	  on	  the	  utility	  of	  ALDH	  activity	  for	  the	  selection	  of	  tumorigenic	  melanoma	  cells	  (64).	  	  ALDH	  has	  been	  shown	  to	  contribute	  to	  resistance	  mechanisms	  to	  radiation	  therapy	  and	  chemotherapy,	  thus	  a	  different,	  more	  specific,	  therapeutic	  approach	  must	  be	  undertaken.	  Some	  groups	  have	  investigated	  chemical	  inhibitors	  (47);	  such	  drug	  development	  requires	  the	  design	  of	  highly	  specific	  inhibitors	  as	  	  the	  widespread	  expression	  of	  ALDH	  in	  healthy	  stem	  cells	  may	  result	  in	  off-­‐target	  effects.	  It	  is	  also	  possible	  that	  functional	  redundancy	  within	  the	  large	  isozyme	  family	  could	  compensate	  for	  inhibition	  of	  one	  ALDH	  target.	  In	  the	  immunotherapy	  setting,	  ALDHhigh	  CSC-­‐loaded	  dendritic	  cells	  have	  been	  used	  successfully	  in	  two	  in	  vivo	  melanoma	  models	  (65,	  66).	  ALDH	  activity	  has	  been	  demonstrated	  in	  the	  regulatory	  T	  cell	  immune	  subset	  in	  the	  transplantation	  setting	  (67);	  thus	  ALDH	  targeting	  may	  also	  have	  an	  anti-­‐tumour	  effect	  via	  affecting	  the	  Treg	  subset.	  
 
Glycolytic	  activity.	  CSCs/TICs	  have	  fewer	  mitochondria	  thus	  they	  are	  more	  glycolytic	  than	  differentiated	  tumour	  cells,	  as	  shown	  in	  melanoma,	  breast,	  lung	  and	  liver	  carcinomas	  (68-­‐71).	  This	  can	  be	  detected	  by	  reduced	  mitochondrial	  activity,	  perinuclear	  mitochondrial	  distribution,	  lower	  intracellular	  concentrations	  of	  ROS	  and	  ATP	  and	  lower	  amounts	  of	  mitochondrial	  DNA	  in	  CSCs/TICs	  (72). 	  CSC/TIC	  inhibitors	  targeting	  either	  self-­‐renewal	  pathways,	  surface	  markers	  or	  enzymes	  have	  potential	  off-­‐target	  effects	  on	  other	  cell	  types.	  Figure	  1	  illustrates	  the	  potential	  side	  effects	  of	  some	  of	  these	  inhibitors	  on	  immune	  cells.	  	  	  	  





(c)	  Function-­‐based	  identification	  	  
	  
Slow	  cell	  division	  of	  CSCs/TICs	  that	  exist	  mostly	  in	  G0	  phase	  can	  be	  detected	  by	  their	  characteristic	  of	  retaining	  dyes	  that	  normally	  become	  diluted	  during	  proliferation,	  such	  as	  PKH,	  BrdU	  or	  CFSE.	  Dye-­‐retaining	  cells	  that	  give	  progeny	  to	  xenotransplants	  have	  been	  observed	  in	  glioma,	  melanoma,	  breast	  and	  pancreatic	  cancer	  (73-­‐77).	  
	  
Enhanced	  drug	  resistance	  and	  detoxifying	  pathways:	  the	  ATP-­‐binding	  cassette	  (ABC)	  transporter	  family	  of	  proteins,	  especially	  ABCB1,	  ABCC1,	  ABCG2,	  and	  ABCB5,	  are	  active	  in	  cancer	  stem	  cells,	  but	  switched	  off	  during	  differentiation	  (78).	  These	  transporter	  proteins	  are	  extremely	  efficient	  in	  pumping	  out	  complex	  molecules	  from	  the	  cytoplasm,	  thus	  protecting	  the	  cells	  from	  exogenous	  toxins,	  including	  numerous	  chemotherapeutic	  drugs.	  They	  have	  a	  wide	  range	  of	  substrates,	  such	  as	  peptides,	  lipids,	  hydrophobic	  drugs,	  polysaccharides	  and	  proteins	  (79).	  Their	  targeting	  with	  specific	  inhibitors	  is	  one	  of	  the	  active	  areas	  of	  drug	  development	  in	  cancer	  (80).	  As	  CSCs/TICs	  also	  exclude	  hydrophobic	  Hoescht	  dyes	  via	  this	  mechanism,	  they	  can	  be	  identified	  by	  forming	  a	  side	  population	  (SP)	  based	  on	  low	  dye	  levels	  (81).	  However,	  ABCB	  proteins,	  such	  as	  TAP,	  also	  have	  an	  important	  role	  in	  intracellular	  peptide	  trafficking	  across	  membranes,	  with	  crucial	  involvement	  in	  major	  histocompatibility	  complex	  (MHC)	  class	  I	  antigen	  presentation	  and	  dendritic	  cell	  function	  (82).	  Thus,	  the	  off-­‐target	  effect	  of	  tumour	  ABCB	  targeting	  may	  be	  deleterious	  for	  generating	  efficient	  anti-­‐tumour	  T	  cell	  responses.	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consequence	  of	  radiation	  damage	  can	  be	  temporary	  or	  permanent	  cell	  cycle	  arrest,	  mainly	  via	  checkpoint	  kinase	  activity	  (Chk-­‐1	  and	  Chk-­‐2),	  which	  allows	  time	  for	  DNA	  damage	  repair	  (DDR)	  to	  take	  place.	  If	  the	  damage	  is	  irreparable,	  DDR	  mediates	  senescence	  or	  cell	  death	  (83).	  ROS	  mediates	  oxidative	  stress,	  which,	  if	  beyond	  the	  capacity	  of	  the	  cell’s	  antioxidant	  defence	  mechanism,	  may	  also	  lead	  to	  cell	  death.	  Both	  DDR	  and	  the	  ROS	  scavenging	  system	  have	  been	  reported	  to	  be	  highly	  efficient	  in	  CSCs/TICs	  in	  numerous	  solid	  cancers	  (84),	  contributing	  to	  their	  intrinsic	  radioresistance.	  Extrinsic	  radioresistance	  may	  be	  supported	  by	  the	  localisation	  of	  CSCs.	  It	  has	  been	  suggested	  that	  CSCs/TICs	  residing	  in	  hypoxic	  areas	  are	  more	  resistant	  to	  radiation-­‐induced	  damage	  than	  cells	  in	  normoxic	  areas.	  Hypoxia-­‐inducing	  factors	  HIF1α	  and	  HIF2α	  may	  lead	  to	  the	  activation	  of	  the	  Notch,	  Wnt	  and	  Hedgehog	  signalling	  pathways,	  which	  are	  essential	  for	  CSC/TIC	  maintenance.	  There	  is	  clinical	  evidence	  that	  radiotherapy	  is	  generally	  less	  successful	  in	  CSC-­‐rich	  laryngeal	  cancer	  where	  CSCs	  were	  identified	  as	  a	  residing	  subset	  within	  the	  CD44high	  population	  (85).	  	  However,	  the	  effects	  of	  hypoxia	  are	  far	  from	  inhibitory	  on	  immune	  cell	  function.	  Activated	  dendritic	  cells	  become	  glycolytic	  and	  their	  long-­‐term	  survival	  is	  regulated	  by	  HIF1α	  (86).	  Effector	  T	  cells	  are	  also	  resistant	  to	  hypoxia	  –	  even	  more,	  their	  cytolytic	  machinery	  is	  turned	  on	  by	  HIF2α	  (87).	  As	  effector	  T	  cells	  also	  display	  glycolytic	  characteristics,	  they	  can	  exert	  their	  effector	  function	  even	  in	  the	  depth	  of	  tissues	  with	  poor	  vasculature,	  maybe	  where	  CSCs/TICs	  reside.	  Furthermore,	  we	  have	  shown	  that	  low	  dose	  radiation	  spares	  effector	  and	  memory	  T	  cells	  as	  compared	  to	  naïve	  T	  cells	  (88).	  Thus,	  combination	  of	  radiation	  with	  T	  cell	  targeting	  of	  stem	  cells	  sounds	  like	  a	  two-­‐pronged	  attack	  with	  potential	  synergistic	  effects.	  	  High	  dose	  radiation	  alone	  may	  eliminate	  CSCs/TICs,	  as	  early	  prostate	  and	  lung	  cancers	  can	  be	  cured	  by	  radiotherapy	  alone.	  It	  may	  partly	  happen	  via	  generating	  immunogenic	  cell	  death,	  which	  then	  initiates	  tumour	  antigen	  uptake	  and	  antigen	  cross-­‐presentation	  by	  dendritic	  cells	  (89).	  One	  could	  speculate	  whether	  radiation-­‐induced	  CSC	  death	  is	  also	  immunogenic	  and	  weather	  radiation	  would	  generate	  CSC/TIC-­‐specific	  effector	  and	  memory	  T	  cells,	  significantly	  contributing	  to	  an	  abscopal	  effect	  and	  subsequent	  protection	  from	  relapse.	  Despite	  its	  obvious	  clinical	  importance,	  this	  question	  has	  not	  been	  studied	  before.	  	  
	  
4.	  Immunological	  characteristics	  of	  CIC/CSC	  
	  
Immunosuppression	  Proliferative	  T	  cell	  responses	  and	  IL-­‐2	  production	  were	  inhibited	  by	  CSCs/TICs	  in	  gliobastoma	  (90)	  and	  melanoma	  (91)	  in	  vitro.	  Treg	  frequencies	  were	  also	  increased	  in	  melanoma	  (91)	  but	  not	  in	  glioblastoma	  CSC–T	  cell	  co-­‐cultures	  (90).	  Secretion	  of	  TGFβ,	  IL-­‐10,	  IL-­‐4	  and	  IL-­‐13	  by	  CSCs/TICs	  has	  been	  shown	  to	  have	  immunosuppressive	  effects	  on	  NK	  cells,	  T	  cells	  and	  antigen	  presenting	  cells	  (90,	  92,	  93).	  Cell	  surface	  molecules,	  such	  as	  CD200,	  expressed	  on	  CSCs/TICs	  (94),	  can	  also	  dampen	  immune	  responses.	  CD200	  overexpression	  has	  been	  associated	  with	  the	  suppression	  of	  Th1	  responses,	  decreased	  neutrophil	  infiltration	  and	  increased	  IL-­‐10	  production	  induced	  by	  the	  tumour,	  as	  shown	  in	  a	  breast	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carcinoma	  model	  (95).	  PD-­‐L1	  is	  often	  overexpressed	  on	  tumour	  cells,	  with	  a	  function	  of	  promoting	  tumour	  glycolysis.	  Upregulation	  on	  CSCs/TICs	  is	  probably	  tumour	  type	  or	  localisation	  dependent,	  as	  e.g.	  hypoxia	  is	  one	  of	  the	  triggers	  that	  can	  upregulate	  PD-­‐L1	  (96).	  High	  expression	  on	  CSCs/TICs	  has	  been	  reported	  on	  head	  and	  neck	  carcinoma	  (36),	  on	  CD133+	  colorectal	  (97)	  and	  gastric	  (98),	  but	  not	  on	  melanoma	  CSCs/TICs	  (91).	  	  
	  




5.	  Potential	  immune	  targeting	  of	  CSCs/TICs	  
	  
a) Antigen	  non-­‐specific	  immune	  targeting	  	  
NK	  cells	  As	  MHC	  Class	  I	  molecule	  expression	  is	  often	  lower	  on	  CSCs/TICs	  than	  on	  the	  bulk	  of	  tumour	  cells,	  CSCs/TICs	  are	  more	  likely	  to	  be	  susceptible	  to	  NK	  cell-­‐mediated	  killing.	  However,	  they	  also	  often	  lack	  NK-­‐activating	  ligands,	  such	  as	  NKG2D,	  as	  shown	  in	  brain	  and	  breast	  cancers	  (101,	  102).	  On	  the	  other	  hand,	  glioma,	  oral	  squamous	  cell	  carcinoma	  and	  colorectal	  cancer	  CSCs/TICs	  (103-­‐105)	  have	  been	  reported	  to	  express	  various	  ligands	  for	  NK	  cells	  (most	  frequently	  PVR	  which	  is	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recognised	  by	  DNAM-­‐1)	  and	  are	  highly	  susceptible	  to	  NK	  cell	  killing.	  However,	  while	  cytokine-­‐activated	  NK	  cells	  have	  efficient	  CSC/TIC	  killing	  ability,	  freshly	  isolated	  NK	  cells	  from	  the	  same	  patient	  do	  not	  kill	  CSCs	  (103).	  This	  points	  towards	  microenvironmental	  regulation	  of	  NK	  cell	  activity	  in	  cancer	  patients.	  	  	  
γδ 	  T	  cells	  	  
γδ	  T	  cells	  also	  exhibit	  MHC-­‐unrestricted	  lysis	  of	  targets,	  including	  tumour	  cells.	  Vγ9Vδ2 T	  cells	  can	  be	  activated	  with	  phosphoantigens	  or	  aminobisphosphonates	  and	  have	  been	  shown	  to	  efficiently	  kill	  CSCs/TICs	  in	  colon,	  ovarian	  and	  breast	  cancer	  models,	  especially	  after	  treatment	  with	  Zoledronate	  (106-­‐108).	  They	  have	  also	  been	  observed	  infiltrating	  the	  tumour	  tissue,	  emphasising	  their	  physiological	  relevance.	  	  	  
b) Antigen-­‐specific	  targeting	  by	  T	  cells	  	  Solid	  cancer	  cells	  and	  their	  CSCs/TICs	  express	  HLA	  Class	  I	  but	  not	  HLA	  Class	  II	  molecules.	  Their	  efficient	  targeting	  by	  CD8+	  T	  cells	  depends	  on	  a	  sufficient	  level	  of	  HLA	  Class-­‐I	  molecule	  expression	  and	  intact	  antigen	  presenting	  machinery	  in	  these	  cells.	  CSC/TIC	  resistance	  or	  susceptibility	  to	  T	  cell	  killing	  has	  both	  been	  reported,	  depending	  on	  tumour	  type,	  origin	  of	  cells	  and	  culture	  conditions.	  Tissue-­‐derived	  CSCs/TICs	  from	  colon	  cancer	  were	  shown	  to	  express	  lower	  levels	  of	  MHC	  Class	  I	  molecules	  than	  non	  stem-­‐like	  cells	  (105).	  	  Some	  TAA,	  such	  as	  MUC-­‐1	  or	  CEP55,	  are	  expressed	  equally	  in	  both	  CSCs/TICs	  and	  non-­‐CSCs/TICs	  (109,	  110),	  while	  others,	  such	  as	  the	  olfactory	  receptor	  family	  7	  subfamily	  C	  member	  1	  (OR7C1)	  are	  dominantly	  expressed	  in	  CSCs/TICs	  (111).	  The	  former	  TAA	  are	  classified	  as	  shared	  antigens	  and	  the	  latter	  are	  functionally	  linked	  to	  cancer	  stemness	  because	  their	  expression	  ceases	  after	  CSC	  differentiation	  into	  non-­‐CSCs.	  T-­‐cell	  responses	  to	  shared	  TAA	  could	  achieve	  temporary	  tumour-­‐control	  but	  it	  may	  lead	  to	  tumor	  escape	  by	  inducing	  loss	  of	  antigens	  that	  are	  not	  necessary	  for	  cellular	  fitness	  (immunoediting)	  (112).	  	  Multiple	  antigen	  targeting,	  incorporating	  those	  TAA	  that	  are	  specifically	  expressed	  in	  CSCs/TICs	  is	  much	  more	  likely	  to	  result	  in	  therapeutic	  success	  in	  clinical	  settings	  (113),	  as	  indicated	  in	  Figure	  2.	  Although	  it	  may	  be	  crucial	  to	  have	  high	  frequencies	  of	  CSC/TIC-­‐specific	  T	  cells	  present	  in	  the	  tumour	  tissue,	  breaking	  the	  localized	  immunosuppressive	  milieu	  is	  likely	  be	  helped	  by	  activated	  infiltrating	  T	  cells	  of	  multiple	  specificity.	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  The	  main	  types	  of	  TAA,	  expressed	  in	  CSCs/TICs	  and	  can	  be	  targeted	  by	  T	  cells,	  are	  summarised	  below.	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Oncofetal	  antigens	  
	  These	  antigens	  are	  typically	  only	  expressed	  during	  embryonic	  development	  in	  fetal	  tissues,	  but	  similarly	  to	  CT	  antigens,	  they	  can	  be	  re-­‐expressed	  in	  some	  cancers.	  A	  typical	  example,	  carcino-­‐embryonic	  antigen	  (CEA)	  is	  expressed	  in	  numerous	  solid	  cancers	  but	  not	  associated	  with	  stem-­‐like	  cells.	  	  Other	  antigens,	  such	  as	  stage	  specific	  embryonic	  antigen	  3	  and	  Globo-­‐H	  are	  expressed	  on	  stem-­‐like	  and	  non	  stem-­‐like	  breast	  cancer	  cells	  at	  similar	  rates	  (119),	  while	  5T4	  is	  preferentially	  expressed	  on	  CSC-­‐like	  cells	  in	  lung	  cancer	  and	  head	  and	  neck	  cancer	  (120)	  (121).	  5T4	  expression,	  in	  both	  malignancies,	  is	  associated	  with	  poor	  prognosis.	  	  Xenograft	  models	  indicated	  that	  the	  CSC-­‐fraction	  can	  be	  reduced,	  tumour	  progression	  halted	  and	  local	  recurrence	  inhibited	  by	  treatment	  with	  an	  antibody-­‐drug	  conjugate	  targeting	  5T4	  (120,	  121).	  	  
	  
Overexpressed	  antigens	  	  This	  group	  of	  antigens	  has	  recently	  been	  reviewed	  by	  Hirohashi	  et	  al.	  (122)	  and	  includes	  apoptosis-­‐resistance	  genes,	  such	  as	  survivin,	  proto-­‐oncogenes,	  such	  as	  HER-­‐2,	  CEP55,	  SOX-­‐2	  and	  COA-­‐1	  (90)	  and	  stress-­‐response	  related	  genes,	  such	  as	  heat	  shock	  protein	  (Hsp)	  or	  HOX	  genes	  (123).	  Some	  of	  the	  overexpressed	  antigens	  are	  general	  stem	  cell-­‐	  and	  not	  exclusively	  cancer	  stem	  cell-­‐specific.	  In	  prostate	  cancer,	  Numb	  has	  been	  identified	  as	  a	  potential	  target	  for	  controlling	  tumourigenesis	  (124).	  Numb	  is	  lost	  in	  differentiating	  tumor	  cells,	  due	  to	  exaggerated	  ubiquitination	  and	  subsequent	  proteasomal	  degradation,	  but	  its	  expression	  is	  maintained	  in	  stem-­‐like	  cells.	  Its	  close	  homologue,	  Numb-­‐like	  (NumbL)	  is	  able	  to	  regulate	  the	  CSC/TIC	  pool	  by	  inhibiting	  the	  Notch	  pathway	  (125).	  Numb-­‐1-­‐	  and	  Notch-­‐specific	  T	  cells	  eliminated	  luminal	  CSC/TIC-­‐like	  cells	  in	  a	  breast	  cancer	  model	  (126).	  In	  a	  gynecological	  cancer	  (endometrioid	  adenocarcinoma),	  ALDHhigh	  cells	  preferentially	  expressed	  Hsp27,	  the	  overexpression	  of	  which	  is	  associated	  with	  poor	  prognosis	  (127).	  MAPK13,	  PTTG1IP,	  CAPN1	  and	  UBQLN2	  were	  also	  found	  highly	  expressed	  in	  these	  cells	  compared	  with	  that	  in	  ALDHlow	  cells	  (128).	  SOX2,	  a	  transcription	  factor	  that	  regulates	  the	  Wnt/β-­‐catenine	  pathway,	  is	  amplified	  in	  numerous	  solid	  tumours	  and	  expressed	  predominantly	  in	  CSCs/TICs	  (129,	  130).	  Interestingly,	  class	  I	  histone	  deacetylase	  (HDAC)	  inhibitors	  increase	  the	  frequency	  of	  SP	  cells	  with	  CSC/TIC	  markers,	  due	  to	  de-­‐differentiation	  of	  cancer	  cells.	  HOXA5	  was	  shown	  to	  be	  the	  main	  transcription	  factor	  responsible	  for	  de-­‐differentiation	  and	  induction	  of	  SOX2	  in	  lung	  cancer	  cells	  (131).	  	  
Differentiation	  antigens	  	  Many	  differentiation	  antigens	  are	  expressed	  in	  primary	  cancer	  cells	  as	  well	  as	  in	  CSC,	  such	  as	  MUC-­‐1	  in	  breast	  cancer,	  tyrosinase	  and	  gp100	  in	  melanoma.	  The	  human	  telomerase	  reverse	  transcriptase	  (hTERT)	  is	  also	  a	  target	  in	  primary	  cancer	  cells	  and	  in	  stem	  cells.	  T	  cells	  have	  been	  generated	  against	  an	  HLA-­‐A3-­‐restricted	  epitope:	  KLFGVLRLK	  (132).	  Successful	  targeting	  of	  these	  antigens	  has	  the	  potential	  of	  eliminating	  CSCs	  and	  non-­‐CSCs	  alike.	  	  
	  
	   13	  
Neoantigens	  	  Although	  CT	  and	  onco-­‐fetal	  antigens	  can	  also	  be	  considered	  as	  neoantigens,	  this	  category	  typically	  includes	  mutated	  tumour	  antigens.	  The	  mutations	  may	  generate	  entirely	  new	  T	  cell	  epitopes	  for	  which	  high	  affinity	  T	  cell	  receptors	  have	  not	  been	  deleted	  during	  development	  and	  thus	  these	  T	  cells	  can	  be	  efficiently	  expanded.	  High	  mutation	  index	  has	  been	  indicated	  to	  be	  the	  underlying	  mechanism	  behind	  successful	  immune	  checkpoint	  inhibitor	  therapy	  (133).	  Although	  it	  is	  yet	  unclear	  weather	  the	  mutation	  index	  of	  CSCs	  is	  different	  from	  that	  of	  primary	  cancer	  cells,	  there	  is	  data	  available	  that	  neoantigens	  are	  present	  in	  colorectal	  cancer	  both	  in	  CSCs	  and	  non-­‐CSCs	  in	  a	  manner	  that	  is	  targetable	  with	  T	  cells	  (134).	  Identifying	  CSC-­‐specific	  neoantigens	  may	  lead	  to	  further	  breakthroughs	  in	  cancer	  immunotherapy.	  	  	  
6.	  Immune	  targeting	  CSCs/TICs	  –	  clinical	  applications	  
	  	  Antigen-­‐specific	  immunological	  targeting	  of	  CSCs/TICs	  requires	  either	  the	  generation	  of	  primary	  T	  cell	  responses,	  reactivation	  of	  memory	  responses	  or	  the	  adoptive	  transfer	  of	  engineered	  antigen-­‐specific	  T	  cells	  into	  the	  host.	  	  Generation	  of	  T	  cell	  responses:	  Most	  clinical	  trials,	  listed	  on	  the	  http://clinicaltrials.gov	  website	  that	  use	  immunotherapy	  and	  target	  cancer	  stem	  cells	  are	  based	  on	  isolating	  CSCs/TICs	  from	  solid	  tumours	  and	  loading	  them	  onto	  dendritic	  cells,	  which	  are	  then	  used	  as	  a	  cancer	  vaccine.	  The	  approach	  is	  based	  on	  pre-­‐clinical	  data	  showing	  the	  success	  of	  this	  approach	  in	  immunocompetent	  mice	  (66).	  Trials	  are	  listed	  in	  pancreatic,	  nasopharyngeal,	  colorectal,	  ovarian,	  lung,	  liver	  and	  brain	  tumours.	  One	  trial	  studied	  the	  outcome	  of	  vaccination	  with	  DC,	  transfected	  with	  hTert	  and	  survivin	  as	  amplified	  ovarian	  CSC	  mRNA	  (NCT01334047).	  The	  stem	  like	  cell-­‐associated	  antigen(s),	  serving	  as	  a	  vaccine	  in	  these	  trials,	  are	  undetermined	  and	  likely	  to	  be	  individual	  patient-­‐specific.	  The	  outcome	  of	  these	  trials	  is	  not	  yet	  publicly	  available,	  however,	  as	  with	  non	  CSCs-­‐DC	  vaccines,	  it	  is	  unlikely	  that	  any	  monotherapy	  alone	  will	  be	  hugely	  effective.	  The	  explosion	  of	  approved	  immunotherapies	  with	  checkpoint	  inhibitors	  opens	  up	  the	  way	  for	  designing	  combination	  therapies.	  However,	  a	  shift	  in	  treatment	  design	  must	  be	  considered:	  vaccines	  or	  redirected	  T	  cells	  should	  be	  targeting	  multiple	  antigens,	  including	  CSC-­‐specific	  ones;	  this	  treatment	  then	  should	  be	  combined	  either	  with	  appropriate	  chemotherapy	  based	  on	  patient	  stratification	  data,	  or	  high	  dose	  radiation	  and/or	  immune	  checkpoint	  inhibitor	  treatments	  in	  order	  to	  provide	  the	  best	  chance	  for	  generating	  robust	  and	  long-­‐lasting	  T	  cell	  responses	  leading	  to	  tumour	  rejection.	  	  	  	  T	  cell	  transfer:	  The	  success	  of	  CAR	  T	  cells	  in	  treating	  hematological	  malignancies	  (https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm)	  generated	  interest	  in	  using	  the	  approach	  against	  solid	  tumours	  and	  CSCs	  as	  well.	  CAR T cells express a chimeric antigen receptor (CAR) which consists 
of an extracellular binding domain of a single-chain fragment of the antibody variable 
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region (scFv) providing antigen-specificity, and the intracellular signalling domains 
of CD3-zeta chain. The receptor can be coupled with co-stimulatory molecules, such 
as CD28 and CD137. Cell surface antigens, expressed on CSCs, such as CD44, 
CD133, aldehyde dehydrogenases (ALDH) and EpCAM can be targeted this way. 
Preclinical work using these CAR T cells in glioblastoma, prostate cancer and 
gynecological tumours have been encouraging (reviewed by Guo (135)). Clinical 
trials are currently ongoing against EGFR and CD133 (NCT01869166 and 
NCT02541370). 	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